Loading



IMAGINE Steering Committee

Peter Nickerson, BSc (Med), MD, FRCPC, FCAHS

Distinguished Professor of Internal Medicine and Immunology and the Vice-Dean Research, Rady Faculty of Health Sciences, University of Manitoba

Dr. Peter Nickerson is a Distinguished Professor of Internal Medicine and Immunology and the Vice-Dean Research, Rady Faculty of Health Sciences at the University of Manitoba. He is the Medical Director of Transplant Manitoba and the Medical Advisor, Organ Donation and Transplantation Division, Canadian Blood Services (CBS).

Dr. Nickerson holds the Flynn Family Chair in Renal Transplantation at the University of Manitoba. Funded by the CIHR and NIH, his research program focuses on mechanisms underlying acute and chronic transplant rejection; developing non-invasive techniques for the diagnosis of renal allograft rejection; and health care system design to enhance access to transplant.

Scott Adler, MD

Executive Director and Global Clinical Therapeutic Area Head for the Transplantation TA, CSL Behring

Scott Adler, MD is the Executive Director and Global Clinical Therapeutic Area Head for the Transplantation TA at CSL Behring. Dr. Adler completed his undergraduate degree in chemistry at Duke University and received his medical degree from the University of Maryland at Baltimore. While a medical student he was a Howard Hughes Medical Institute – National Institutes of Health Research Scholar. He then completed his Internal Medicine training at Duke University Medical Center and Nephrology Fellowship at the Hospital of the University of Pennsylvania. Following his fellowship he served as Instructor of Medicine and attending physician on the Kidney Transplantation Service and holds Board Certification in Nephrology. Dr. Adler has over 15 years of pharmaceutical industry experience with leadership roles in clinical pharmacology and experimental medicine, translational patient safety and late stage clinical development. He has extensive experience in the Transplantation, Immunology, Cardiovascular and Renal Medicine therapeutic areas and has held important clinical leadership roles during the NDA and MAA submission and approval process for 2 recently approved drugs.

Georg Böhmig, MD

Associate Professor of Medicine at the Division of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna

Dr. Georg Böhmig is Associate Professor of Medicine at the Division of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna, Austria. He received his MD degree from the University of Vienna in 1993. 1991-96 he was trained at the Vienna Institute of Immunology. Since 1996, he is employed at the Division of Nephrology and Dialysis, where he obtained licences for Internal Medicine (2002), Nephrology (2005) and Intensive Care Medicine (2011). Georg Böhmig has advanced to associate professor in 2002. Since 2003 he is coordinator of the Vienna kidney transplant wait list, the Vienna kidney paired donation program and ABO- and HLA antibody-incompatible kidney transplantation programs. His published work includes more than 150 peer-reviewed journal articles with continuous focus on translational research in transplant immunology. Major research interests of his group cover diagnostic and therapeutic aspects of antibody-mediated organ allograft rejection. Current projects focus on novel strategies for ex-vivo monitoring of humoral alloresponses and evaluation of “anti-humoral” treatment strategies including apheresis (crossmatch conversion, ABO antibody depletion, rejection treatment), complement interference, proteasome inhibition, or IL-6 antagonism.

Steve Chadban, BMed(hons), PhD, FAAHMS, FRACP

Director of Renal Medicine, State-wide Renal Services, Royal Prince Alfred Hospital, Sydney, Australia
Professor of Medicine, Kidney Hub-CPC, University of Sydney, Australia

Professor Steve Chadban received the University Medal for Medicine at the University of Newcastle, completed physician training in Newcastle, Nephrology training and a PhD at Monash, Victoria, Australia. Following his PhD, Chadban took a post-doctoral position studying immunology at the University of Cambridge, UK. He returned to Monash University to run the Transplantation Program from 1999–2002 before moving to the Royal Prince Alfred Hospital, Sydney, Australia, where he is Area Director of Renal Medicine, Senior Staff Nephrologist, Professor of Medicine (Nephrology) and Leader of the Kidney Node, Charles Perkins Centre, University of Sydney.

Professor Chadban is Past-President of the Transplantation Society of Australia and New Zealand and Councillor of The Transplantation Society (Oceania Rep), Executive Member of ANZDATA and a Lead Investigator in the CARSK and AusDiab Kidney Studies. Chadban advises Government as Chair of the Transplant Liason Reference Group (Organ and Tissue Authority) and National Vascular Diseases Advisory Group/CKD(AIHW). Chadban is Associate Editor for Transplantation. He has spoken at numerous national and international meetings and has produced over 250 papers published in journals including the New England Journal of Medicine, JAMA, Lancet and the Journal of Clinical Investigation. His publications have been cited 14,197 times and his H-index is 59. Research interests include CKD and ESKD epidemiology, the molecular mechanisms of transplant rejection and CKD, with a focus on innate immunity, and improving outcomes for kidney transplant recipients through clinical trials. 

Arjang Djamali, MD, MS, FASN

Division Head of Nephrology, University of Wisconsin Madison School of Medicine and Public Health

Dr. Arjang Djamali is currently the Division Head of Nephrology at the University of Wisconsin Madison School of Medicine and Public Health, where he also practices as a transplant nephrologist. The goal of Dr. Djamali’s research program is to improve the health and well-being of patients with transplant kidney disease. He has addressed this topic using basic, clinical, and translational studies at one of the finest transplant centers in the world. Dr. Djamali’s clinical research includes trials and observational studies that address disease progression/outcomes and antibody-mediated processes in kidney transplant recipients. His basic and translational research focus on the molecular and cellular mechanisms that regulate allograft rejection and fibrosis. Dr. Djamali’s research has been funded by Foundations, Industry, and the National Institute of Health. He has been a frequent invited speaker in the US, Europe, and Asia.

Teun van Gelder, MD, PhD

Professor, Drug Discovery & Development, Leiden University Medical Center

Dr. Teun van Gelder is an internist-nephrologist and clinical pharmacologist. He was trained in internal medicine and nephrology at the Erasmus Medical Center, and completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a post-doctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr. Randall E. Morris at Stanford University (1998-2000), and was awarded the Young Investigator Award from the American Society for Transplantation for his work during this time.

Between 2000 and 2019 he worked in the Departments of Hospital Pharmacy and Internal Medicine at the Erasmus Medical Center in Rotterdam, the Netherlands. In 2010, at Erasmus Medical Center he was appointed Professor in Clinical Pharmacology. His research at the Erasmus Medical Center was focused on clinical pharmacology and therapeutic drug monitoring. He was the chairman of the Dutch Society for Clinical Pharmacology & Biopharmacy, the secretary of the Dutch Society for Transplantation, and the President of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology.

In December 2019 Teun van Gelder accepted a new position in Leiden University Medical Center (LUMC). He was appointed Professor in Drug Discovery & Development. LUMC, Leiden Institute of Chemistry, Leiden Academic Centre for Drug Research (LACDR), Centre for Human Drug Research (CHDR) and Leiden Bio Science Park (LBSP) together have the expertise and facilities for the design, development and testing of new innovative drugs. This environment is unique in the Netherlands, and provides an excellent basis for drug discovery and drug development. In his role as an experienced internist – clinical pharmacologist Teun will make an important contribution to Academic Pharma.

Deepali Kumar, MD, MSc, FRCP(c)

Professor of Medicine, University of Toronto

Dr. Deepali Kumar is Professor of Medicine at the University of Toronto. She is attending physician in the Multi-Organ Transplant Program, Transplant Infectious Diseases service at University Health Network. Dr. Kumar has a translational research program that focuses on immunologic responses to viral infections and vaccines in transplant recipients. She has performed several investigator-initiated and industry clinical trials in transplantation. Dr. Kumar has authored over 175 manuscripts, editorials, and book chapters in the field of transplantation. For her research she has been a recipient of the American Society of Transplantation Clinical Investigator Award (2018) and the Royal College Gold Medal in Medicine (2010). She is Editor-in-chief of The AST Handbook of Transplant Infections and Associate Editor of the 4th AST Transplant ID Guidelines.

Roslyn B. Mannon, MD, FASN

Professor of Medicine, University of Nebraska Medical Center, Associate Division Director of Nephrology for Research and Vice Chair of Medicine for Research and Academic Development

Dr. Roslyn Bernstein Mannon is a Professor of Medicine at the University of Nebraska Medical Center, Associate Division Director of Nephrology for research and Vice Chair of Medicine for research and academic development. Dr. Mannon is a Fellow of the American Society of Nephrology and AST. She received her MD from Duke University, completing Internal Medicine internship, residency and Nephrology fellowship and Chief Resident at Duke. Dr. Mannon is a past-president of the AST and is a Deputy Editor for the American Journal of Transplantation. Mannon’s laboratory research focuses on mechanisms of chronic graft injury using in vitro and using rodent models of drug toxicity and kidney transplantation and is funded by the Veterans Administration Merit Award. Dr. Mannon is site PI for the Clinical Trials in Organ Transplantation (CTOT), and a member of the CTOT Steering Committee. She serves as a member of the Steering Committee for the Transplant Therapeutics Consortium, a private/public partnership with cPATH and FDA. She has published over 200 peer-reviewed publications on the mechanisms of chronic allograft failure following transplantation.

Edward Chong, MBChB, MRCP, Dip Pharm Med

Chief Medical Officer, Vitaeris

Dr. Chong is a physician with over 25 years of drug development experience in the pharmaceutical industry. During this period, he has worked in large and small pharmaceutical companies and across several therapeutic areas. He has achieved a track record of designing and implementing global clinical development programs resulting in several successful regulatory submissions in the USA and Europe.​

Prior to this role, Dr. Chong served as Vice President, Clinical Research at Aspreva Pharmaceuticals, and then subsequent to its sale, as Vice President responsible for global clinical research and biometrics at Vifor Pharma. Dr. Chong received his undergraduate medical education and post-graduate training in internal medicine and cardiology in the Universities of Dundee and Glasgow, Scotland.

Vitaeris is now part of CSL Behring! We are pleased to become part of CSL Behring, a well-established, global industry leader, and know that the future of clazakizumab is in excellent hands. Together, we have already achieved much progress through our partnership over the past few years and are now in an even stronger position to realize our collective goal of addressing one of the greatest unmet needs in the organ transplant community.

Learn more